As high-profile drugs like Abbvie's Humira and Bristol Myers Squibb's (BSQ) prepare to face increased competition in the form of biosimilars, a slate of drugs worth are set to lose their exclusivity. A new article from Fierce Pharma lists the top 10 of these blockbuster and best-selling drugs, collectively accounting for $17 billion in sales annually. The priciest of these is BSQ's multiple myeloma drug, Revlimid, whose sales top $8.7 billion each year. The drug's loss of exclusivity comes after substantial price hikes that spurred a congressional investigation.
According to the article, “In 2020, Congress took Celgene and BMS to task after a probe found the companies raised prices on Revlimid more than 20 times to hit aggressive sales targets. Once priced at $215 per pill, Revlimid now goes for $870 before rebates and discounts, the probe found. Lawmakers concluded the company's tactics were “anti-competitive” yet all within the laws of the land Congress controls.”
Read the rest of the list by clicking here.
(Source: Fierce Pharma, March 8th, 2022)
